Global Gallstone Solubilizing Agents Market – Industry Trends and Forecast to 2029

 Market Analysis and Size  

Gallstones are solidified digestive fluid deposits that occur in the gallbladder. They can be made up of cholesterol, salt, or bilirubin and come in various sizes. They can range in size from a grain of sand to an apricot. Gallstones afflict 10-15percent of the U.S. population every year, or approximately 25 million individuals, as per a 2017 report from the American Gastroenterological Association. Gallstones are becoming more popular as people consume more fat and cholesterol in their diet. All these factors lead to the introduction of gallstone solubilizing agents? in the market.

Data Bridge Market Research analyses that the gallstone solubilizing agents? market was valued at USD 534.98 million in 2021 and is expected to reach USD 723.19 million by 2029, registering a CAGR of 4% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Gallstone solubilizing chemicals dissolve small non-calcified gallstones. They reduce the quantity of cholesterol produced by the liver or prevent cholesterol from being absorbed by the intestines. They are used to dissolve gallstones in people who do not require surgery.

Report Scope and Market Segmentation

Gallstone Solubilizing Agents? Market Dynamics

Drivers

• Rise in the prevalence of gallbladder disease

The rising prevalence of gallbladder disease is anticipated to enhance the antifungal drugs market's growth rate. Along with this, the growing incidences of primary biliary cholangitis will propel the demand for gallstone solubilizing agents? in the market during the forecast period.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of gallstone solubilizing agents? market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the gallstone solubilizing agents? market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of gallstone solubilizing agents? market. Along with this, rising geriatric population and favourable reimbursement scenario will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the gallstone solubilizing agents? market growth. The surge in drug approvals and new product launches will further propel the market's growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the gallstone solubilizing agents? market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and low awareness among people will challenge the gallstone solubilizing agents? market. Additionally, side effects of gallstone solubilizing agents? including nausea, vomiting, dizziness, hair loss, back pain, cough, and others will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This gallstone solubilizing agents? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the gallstone solubilizing agents? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Gallstone solubilizing agents? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Gallstone Solubilizing Agents ? Market

Over the projected period, the gallstone solubilizing agents market is expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations have imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world are having difficulty continuing their supply chain activities. The supply chain slowness has also hampered the gallstone solubilizing agents? market.

Global Gallstone Solubilizing Agents? Market Scope

The gallstone solubilizing agents? market is segmented on the basis of drug type, application, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Ursodiol
• Chenodeoxycholic Acid

Application

• Gallbladder Disease
• Primary Biliary Cholangitis
• Others

Dosage Form

• Capsule
• Tablet
• Others

Route of Administration

• Oral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Gallstone Solubilizing Agents Market Regional Analysis/Insights

The Gallstone solubilizing agents? market is analysed and market size insights and trends are provided by country, drug type, application, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Gallstone solubilizing agents? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the gallstone solubilizing agents market because of the increase in the number of research and development activities in this region. Additionally, the growing presence of major key players and well-established healthcare infrastructure will further propel themarket's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to rising healthcare expenditure and increasing government initiatives for the improvement of healthcare infrastructure in this region. Also, growing geriatric populations and rising level of disposable income with will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Gallstone Solubilizing Agents Market Share Analysis

The Gallstone solubilizing agents? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to gallstone solubilizing agents? market.

Some of the major players operating in the gallstone solubilizing agents? market are:

• Dipharma Francis S.r.l. (Italy)
• ERREGIERRE S.p.A. (Italy)
• Grindeks (Latvia)
• ICE S.p.A. (Italy)
• Zhongshan Belling Biotechnology Co.,Ltd. (China)
• Abil Chempharma Private Limited (India)
• Biotavia (India)
• DAEWOONG BIO (South Korea)
• PharmaZell GmbH (Germany)
• Suzhou Tianlu Bio-pharmaceutical Co., Ltd. (China)
• Glenmark Pharmaceuticals Limited (India)
• Mitsubishi Tanabe Pharma Corporation (Japan) 

SKU-68130